273 related articles for article (PubMed ID: 23550732)
1. Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis.
Xia G; Santostefano KE; Goodwin M; Liu J; Subramony SH; Swanson MS; Terada N; Ashizawa T
Cell Reprogram; 2013 Apr; 15(2):166-77. PubMed ID: 23550732
[TBL] [Abstract][Full Text] [Related]
2. Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro.
Xia G; Santostefano K; Hamazaki T; Liu J; Subramony SH; Terada N; Ashizawa T
J Mol Neurosci; 2013 Oct; 51(2):237-48. PubMed ID: 23224816
[TBL] [Abstract][Full Text] [Related]
3. Recapitulating muscle disease phenotypes with myotonic dystrophy 1 induced pluripotent stem cells: a tool for disease modeling and drug discovery.
Mondragon-Gonzalez R; Perlingeiro RCR
Dis Model Mech; 2018 Jul; 11(7):. PubMed ID: 29898953
[TBL] [Abstract][Full Text] [Related]
4. Lymphoblastoids cell lines - Derived iPSC line from a 26-year-old myotonic dystrophy type 1 patient carrying (CTG)
Martineau L; Racine V; Benichou SA; Puymirat J
Stem Cell Res; 2018 Jan; 26():103-106. PubMed ID: 29274549
[TBL] [Abstract][Full Text] [Related]
5. Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells.
Xia G; Gao Y; Jin S; Subramony SH; Terada N; Ranum LP; Swanson MS; Ashizawa T
Stem Cells; 2015 Jun; 33(6):1829-38. PubMed ID: 25702800
[TBL] [Abstract][Full Text] [Related]
6. Modelling the pathogenesis of Myotonic Dystrophy type 1 cardiac phenotype through human iPSC-derived cardiomyocytes.
Spitalieri P; Talarico RV; Caioli S; Murdocca M; Serafino A; Girasole M; Dinarelli S; Longo G; Pucci S; Botta A; Novelli G; Zona C; Mango R; Sangiuolo F
J Mol Cell Cardiol; 2018 May; 118():95-109. PubMed ID: 29551391
[TBL] [Abstract][Full Text] [Related]
7. Generation of three myotonic dystrophy type 1 patient iPSC lines (CBRCULi018-A, CBRCULi019-A, CBRCULi020-A) derived from lymphoblastoid cell lines for disease modelling and therapeutic research.
Pierre M; Jauvin D; Puymirat J; Boutjdir M; Chahine M
Stem Cell Res; 2024 Apr; 76():103375. PubMed ID: 38490135
[TBL] [Abstract][Full Text] [Related]
8. Distinct pathological signatures in human cellular models of myotonic dystrophy subtypes.
Kim EY; Barefield DY; Vo AH; Gacita AM; Schuster EJ; Wyatt EJ; Davis JL; Dong B; Sun C; Page P; Dellefave-Castillo L; Demonbreun A; Zhang HF; McNally EM
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30730308
[TBL] [Abstract][Full Text] [Related]
9. Generation of two induced pluripotent stem cells lines from a Mucopolysaccharydosis IIIB (MPSIIIB) patient.
Vallejo-Diez S; Fleischer A; Martín-Fernández JM; Sánchez-Gilabert A; Bachiller D
Stem Cell Res; 2018 Dec; 33():180-184. PubMed ID: 30408744
[TBL] [Abstract][Full Text] [Related]
10. Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery.
Jang J; Yoo JE; Lee JA; Lee DR; Kim JY; Huh YJ; Kim DS; Park CY; Hwang DY; Kim HS; Kang HC; Kim DW
Exp Mol Med; 2012 Mar; 44(3):202-13. PubMed ID: 22179105
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Stability and Differentiation Potential of Cryopreserved cGMP-Compliant Human Induced Pluripotent Stem Cells.
Shafa M; Walsh T; Panchalingam KM; Richardson T; Menendez L; Tian X; Suresh Babu S; Dadgar S; Beller J; Yang F; Baghbaderani BA
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877913
[TBL] [Abstract][Full Text] [Related]
12. Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy.
Gao Y; Guo X; Santostefano K; Wang Y; Reid T; Zeng D; Terada N; Ashizawa T; Xia G
Mol Ther; 2016 Aug; 24(8):1378-87. PubMed ID: 27203440
[TBL] [Abstract][Full Text] [Related]
13. Generation of induced pluripotent stem cell line(ZZUi006-A)from a patient with myotonic dystrophy type 1.
Wang Y; Wang Z; Sun H; Shi C; Yang J; Liu Y; Liu H; Zhang S; Zhang L; Xu Y; Zhang J
Stem Cell Res; 2018 Oct; 32():61-64. PubMed ID: 30216892
[TBL] [Abstract][Full Text] [Related]
14. Induced pluripotent stem cell (iPSC) line (HEBHMUi002-A) from a healthy female individual and neural differentiation.
Ma J; Zhang J; He J; Zhang Z; Li W; Feng B; Guo R; Amponsah AE; Kong D; Liu A; Song Y; Wei L; Cui H
Stem Cell Res; 2020 Jan; 42():101669. PubMed ID: 31791011
[TBL] [Abstract][Full Text] [Related]
15. Generation of induced pluripotent stem cell line (ZZUi015-A) from a DM1 patient with cataract.
Li T; Sun H; Wang Z; Zhang Q; Chen N; Zhang K; Wang Y; Xu Y
Stem Cell Res; 2022 Jan; 58():102623. PubMed ID: 34915310
[TBL] [Abstract][Full Text] [Related]
16. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.
Juopperi TA; Kim WR; Chiang CH; Yu H; Margolis RL; Ross CA; Ming GL; Song H
Mol Brain; 2012 May; 5():17. PubMed ID: 22613578
[TBL] [Abstract][Full Text] [Related]
17. Generation of four myotonic dystrophy type 1 patient iPSC lines (CBRCULi002-A, CBRCULi003-A, CBRCULi004-A, CBRCULi005-A) and a control (CBRCULi001-A) derived from lymphoblastoids cell lines.
Jauvin D; Pierre M; Boutjdir M; Puymirat J; Chahine M
Stem Cell Res; 2023 Mar; 67():103037. PubMed ID: 36739767
[TBL] [Abstract][Full Text] [Related]
18. Human induced pluripotent stem cell-derived neural stem cells survive, migrate, differentiate, and improve neurologic function in a rat model of middle cerebral artery occlusion.
Yuan T; Liao W; Feng NH; Lou YL; Niu X; Zhang AJ; Wang Y; Deng ZF
Stem Cell Res Ther; 2013 Jun; 4(3):73. PubMed ID: 23769173
[TBL] [Abstract][Full Text] [Related]
19. Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds.
Arandel L; Polay Espinoza M; Matloka M; Bazinet A; De Dea Diniz D; Naouar N; Rau F; Jollet A; Edom-Vovard F; Mamchaoui K; Tarnopolsky M; Puymirat J; Battail C; Boland A; Deleuze JF; Mouly V; Klein AF; Furling D
Dis Model Mech; 2017 Apr; 10(4):487-497. PubMed ID: 28188264
[TBL] [Abstract][Full Text] [Related]
20. The Autism Spectrum Disorders Stem Cell Resource at Children's Hospital of Orange County: Implications for Disease Modeling and Drug Discovery.
Brick DJ; Nethercott HE; Montesano S; Banuelos MG; Stover AE; Schutte SS; O'Dowd DK; Hagerman RJ; Ono M; Hessl DR; Tassone F; Schwartz PH
Stem Cells Transl Med; 2014 Nov; 3(11):1275-86. PubMed ID: 25273538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
